JP2024536869A - イミダゾピリダジンil-17阻害剤化合物 - Google Patents
イミダゾピリダジンil-17阻害剤化合物 Download PDFInfo
- Publication number
- JP2024536869A JP2024536869A JP2024518884A JP2024518884A JP2024536869A JP 2024536869 A JP2024536869 A JP 2024536869A JP 2024518884 A JP2024518884 A JP 2024518884A JP 2024518884 A JP2024518884 A JP 2024518884A JP 2024536869 A JP2024536869 A JP 2024536869A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- compound
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248566P | 2021-09-27 | 2021-09-27 | |
| US63/248,566 | 2021-09-27 | ||
| US202163273422P | 2021-10-29 | 2021-10-29 | |
| US63/273,422 | 2021-10-29 | ||
| US202263367546P | 2022-07-01 | 2022-07-01 | |
| US63/367,546 | 2022-07-01 | ||
| PCT/US2022/077001 WO2023049887A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536869A true JP2024536869A (ja) | 2024-10-08 |
| JP2024536869A5 JP2024536869A5 (cg-RX-API-DMAC7.html) | 2025-09-19 |
Family
ID=83692741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518884A Pending JP2024536869A (ja) | 2021-09-27 | 2022-09-26 | イミダゾピリダジンil-17阻害剤化合物 |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026505057A (ja) * | 2023-01-30 | 2026-02-10 | ダイス・アルファ・インコーポレイテッド | ベンズイミダゾール及びアザ-ベンズイミダゾール系のil-17aモジュレータ並びにその使用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| EP4688156A1 (en) * | 2023-03-28 | 2026-02-11 | Janssen Pharmaceutica NV | Lactam-containing imidazopyridazine il-17 inhibitor compounds |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024215597A1 (en) * | 2023-04-11 | 2024-10-17 | Dice Alpha, Inc. | Substituted 6-imidazopyridazine il-17a modulators and uses thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020146194A1 (en) * | 2019-01-07 | 2020-07-16 | Eli Lilly And Company | Imidazo[1,2-b]pyridazine il-17a inhibitors |
| WO2020261141A1 (en) * | 2019-06-26 | 2020-12-30 | UCB Biopharma SRL | Imidazopyridine derivatives as il-17 modulators |
| CN112341450A (zh) * | 2019-08-09 | 2021-02-09 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| JP2021510707A (ja) * | 2018-01-15 | 2021-04-30 | ユーシービー バイオファルマ エスアールエル | Il−17モジュレータとしての縮合イミダゾール誘導体 |
| CN112824398A (zh) * | 2019-11-20 | 2021-05-21 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021170627A1 (en) * | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664947B2 (ja) | 2020-04-30 | 2025-04-18 | ヤンセン ファーマシューティカ エヌ.ベー. | Il-17の調節因子としてのイミダゾリダジン |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
-
2022
- 2022-09-26 AU AU2022349687A patent/AU2022349687A1/en active Pending
- 2022-09-26 UY UY0001039958A patent/UY39958A/es unknown
- 2022-09-26 JP JP2024518884A patent/JP2024536869A/ja active Pending
- 2022-09-26 IL IL311751A patent/IL311751A/en unknown
- 2022-09-26 PE PE2024000594A patent/PE20240935A1/es unknown
- 2022-09-26 TW TW111136301A patent/TW202330530A/zh unknown
- 2022-09-26 WO PCT/US2022/077001 patent/WO2023049887A1/en not_active Ceased
- 2022-09-26 CA CA3233408A patent/CA3233408A1/en active Pending
- 2022-09-26 KR KR1020247013352A patent/KR20240082369A/ko active Pending
- 2022-09-26 US US17/935,360 patent/US12173007B2/en active Active
- 2022-09-26 EP EP22790174.1A patent/EP4408847A1/en active Pending
- 2022-09-26 MX MX2024003772A patent/MX2024003772A/es unknown
-
2024
- 2024-03-14 DO DO2024000051A patent/DOP2024000051A/es unknown
- 2024-03-22 CO CONC2024/0003723A patent/CO2024003723A2/es unknown
- 2024-03-25 CL CL2024000867A patent/CL2024000867A1/es unknown
- 2024-03-26 JO JOJO/P/2024/0059A patent/JOP20240059A1/ar unknown
- 2024-10-04 US US18/906,207 patent/US20250109137A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021510707A (ja) * | 2018-01-15 | 2021-04-30 | ユーシービー バイオファルマ エスアールエル | Il−17モジュレータとしての縮合イミダゾール誘導体 |
| WO2020146194A1 (en) * | 2019-01-07 | 2020-07-16 | Eli Lilly And Company | Imidazo[1,2-b]pyridazine il-17a inhibitors |
| WO2020261141A1 (en) * | 2019-06-26 | 2020-12-30 | UCB Biopharma SRL | Imidazopyridine derivatives as il-17 modulators |
| CN112341450A (zh) * | 2019-08-09 | 2021-02-09 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112824398A (zh) * | 2019-11-20 | 2021-05-21 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021170627A1 (en) * | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026505057A (ja) * | 2023-01-30 | 2026-02-10 | ダイス・アルファ・インコーポレイテッド | ベンズイミダゾール及びアザ-ベンズイミダゾール系のil-17aモジュレータ並びにその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330530A (zh) | 2023-08-01 |
| JOP20240059A1 (ar) | 2024-03-26 |
| WO2023049887A1 (en) | 2023-03-30 |
| CO2024003723A2 (es) | 2024-04-18 |
| PE20240935A1 (es) | 2024-04-30 |
| KR20240082369A (ko) | 2024-06-10 |
| UY39958A (es) | 2023-04-28 |
| US20230143050A1 (en) | 2023-05-11 |
| AU2022349687A1 (en) | 2024-05-16 |
| MX2024003772A (es) | 2024-06-19 |
| DOP2024000051A (es) | 2024-11-15 |
| CL2024000867A1 (es) | 2024-09-23 |
| CA3233408A1 (en) | 2023-03-30 |
| EP4408847A1 (en) | 2024-08-07 |
| US20250109137A1 (en) | 2025-04-03 |
| IL311751A (en) | 2024-05-01 |
| US12173007B2 (en) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12173007B2 (en) | Imidazopyridazine IL-17 inhibitor compounds | |
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| US11702422B2 (en) | Imidazopyridazines as modulators of IL-17 | |
| CN107949559B (zh) | 作为irak4调节剂的双环稠合杂芳基或芳基化合物 | |
| DK3077395T3 (en) | PYRROLO [2,3-D] PYRIMIDINYL, PYRROLO [2,3-B] PYRAZINYL AND PYRROLO [2,3-D] PYRIDINYL ACRYLAMIDS | |
| CN121843944A (zh) | 大环化合物及其抗体-药物偶联物 | |
| US11897900B2 (en) | Inhibitors of KEAP1-Nrf2 protein-protein interaction | |
| JP2020143162A (ja) | キナーゼ阻害剤としてのピラゾロピリミジン誘導体 | |
| JP2020055859A (ja) | ヤヌスキナーゼ阻害薬としての4,6−置換−ピラゾロ[1,5−a]ピラジン | |
| US12215111B2 (en) | Imidazopyridazine IL-17 inhibitor compounds | |
| JP2023528334A (ja) | Il-17aモジュレーター | |
| JP2026503702A (ja) | 神経変性疾患の処置に有用な1-アミノ-4-フェニルフタラジン誘導体 | |
| WO2018141842A1 (en) | 5-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NOVEL JAK KINASE INHIBITORS | |
| EP4688156A1 (en) | Lactam-containing imidazopyridazine il-17 inhibitor compounds | |
| JP7627269B2 (ja) | RORγt阻害剤、その製造方法及び使用 | |
| EA049269B1 (ru) | Соединения ингибиторов il-17 на основе имидазопиридазина | |
| CN118317962A (zh) | 咪唑并哒嗪il-17抑制剂化合物 | |
| WO2025146502A1 (en) | Coronavirus inhibiting compounds | |
| CN118076606A (zh) | 咪唑并哒嗪il-17抑制剂化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250910 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250910 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260609 |